



TEXTBOOK OF

# Pharmacoepidemiology

Third Edition

Edited by  
**Brian L. Strom**  
**Stephen E. Kimmel**  
**Sean Hennessy**

**WILEY** Blackwell

# Table of Contents

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[List of Contributors](#)

[Preface](#)

[Acknowledgments](#)

[Part I: Introduction to Pharmacoepidemiology](#)

[1 What is Pharmacoepidemiology?](#)

[Introduction](#)

[Definition of Pharmacoepidemiology](#)

[Historical Background](#)

[The Current Drug Approval Process](#)

[Potential Contributions of  
Pharmacoepidemiology](#)

[Key Points](#)

[Further Reading](#)

[2 Study Designs Available for  
Pharmacoepidemiologic Studies](#)

[Introduction](#)

[Overview of the Scientific Method](#)

[Types of Errors that one Can Make in  
Performing a Study](#)

[Criteria for the Causal Nature of an Association](#)

[Epidemiologic Study Designs](#)

[Discussion](#)

[Conclusion](#)

[Key Points](#)

[Further Reading](#)

### [3 Sample Size Considerations for Pharmacoepidemiologic Studies](#)

[Introduction](#)

[Sample Size Calculations for Cohort Studies](#)

[Sample Size Calculations for Case-Control  
Studies](#)

[Sample Size Calculations for Case Series](#)

[Discussion](#)

[Key Points](#)

[Further Reading](#)

### [4 Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies](#)

[Introduction](#)

[Clinical Pharmacology and  
Pharmacoepidemiology](#)

[Basics of Clinical Pharmacology](#)

[Pharmacokinetics](#)

[Special Populations](#)

[Pharmacodynamics](#)

[Pharmacogenomics](#)

[Model-Informed Drug Development](#)

[Conclusion](#)

[Key Points](#)

[Further Reading](#)

### [5 When Should One Perform Pharmacoepidemiologic Studies?](#)

[Introduction](#)

[Reasons to Perform Pharmacoepidemiologic Studies](#)

[Safety Versus Risk](#)

[Risk Tolerance](#)

[Conclusion](#)

[Key Points](#)

[Further Reading](#)

[6 Views from Academia, Industry, Regulatory Agencies, and the Legal System](#)

[The View from Academia](#)

[The View from Industry](#)

[The View from Regulatory Agencies](#)

[The View from the Legal System](#)

[Further Reading](#)

[Part II: Sources of Pharmacoepidemiology Data](#)

[7 Postmarketing Spontaneous Pharmacovigilance Reporting Systems](#)

[Introduction](#)

[Description](#)

[Strengths](#)

[Limitations](#)

[Particular Applications](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)

[8 Overview of Electronic Databases in Pharmacoepidemiology](#)

[Introduction](#)

[Description](#)

[Strengths](#)

[Weaknesses](#)

[Particular Applications](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)

## [9 Encounter Databases](#)

[Introduction](#)

[Description](#)

[Strengths](#)

[Limitations](#)

[Particular Applications](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)

[US Databases](#)

[European Databases](#)

[Canadian Databases](#)

[Asian Databases](#)

## [10 Electronic Health Record Databases](#)

[Introduction](#)

[Description](#)

[Strengths](#)

[Limitations](#)

[The Future](#)

[Summary Points for Electronic Health Record  
Databases](#)

[Acknowledgment](#)

## Further Readings

### 11 Primary Data Collection for Pharmacoepidemiology.

#### Introduction

#### Methods of Primary Data Collection

#### Strengths

#### Limitations

#### Particular Applications

#### Conclusions

#### Key Points

#### Further Reading

### 12 How Should One Perform Pharmacoepidemiologic Studies? Choosing Among the Available Alternatives

#### Introduction

#### Choosing Among the Available Approaches to Pharmacoepidemiologic Studies

#### Examples

#### Conclusion

#### Key Points

#### Further Reading

## Part III: Special Issues in Pharmacoepidemiology. Methodology.

### 13 Validity of Drug and Diagnosis Data in Pharmacoepidemiology.

#### Introduction

#### Clinical Problems to be Addressed by Pharmacoepidemiologic Research

#### Methodological Problems to be Solved by Pharmacoepidemiologic Research

[Currently Available Solutions](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)

## [14 Assessing Causality from Case Reports](#)

[Introduction](#)

[Clinical Problems to be Addressed by  
Pharmacoepidemiologic Research](#)

[The Two Paradigms of Causality Assessment](#)

[When is Assessing Causation from Cases  
Reports Useful?](#)

[Methodological Problems to be Addressed by  
Pharmacoepidemiologic Research](#)

[Approaches for Assessing Causation from  
Individual Cases](#)

[Calibration](#)

[Choosing the Appropriate Approach](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)

## [15 Molecular Pharmacoepidemiology](#)

[Introduction](#)

[Definitions and Concepts](#)

[The Interface of Pharmacogenetics and  
Pharmacogenomics with Molecular  
Pharmacoepidemiology](#)

[Clinical Problems to be Addressed by  
Pharmacoepidemiologic Research](#)

[The Progression and Clinical Application of  
Molecular Pharmacoepidemiology](#)

[Methodological Problems to be Addressed by  
Pharmacoepidemiologic Research](#)

[Currently Available Solutions](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)

[16 Bioethical Issues in Pharmacoepidemiologic  
Research](#)

[Introduction](#)

[Clinical Problems to be Addressed by  
Pharmacoepidemiologic Research](#)

[Methodologic Problems to be Solved by  
Pharmacoepidemiologic Research](#)

[Currently Available Solutions](#)

[The Future](#)

[Acknowledgement](#)

[Key Points](#)

[Further Reading](#)

[17 The Use of Randomized Controlled Trials for  
Pharmacoepidemiology](#)

[Introduction](#)

[Clinical Problems to be Addressed by  
Pharmacoepidemiologic Research](#)

[Methodological Problems to be Solved by  
Pharmacoepidemiologic Research](#)

[Currently Available Solutions](#)

[Analysis](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)



## 18 Pharmacoeconomics

Introduction

Clinical Problems to be Addressed by  
Pharmacoeconomic Research

Methodological Problems to be Addressed by  
Pharmacoeconomic Research

The Future

Acknowledgements

Key Points

Further Reading

## 19 Patient Engagement and Patient Reported Outcomes

Introduction

Patient Reported Outcomes in Clinical Trials

Patient Reported Outcomes in Routine Care

Patient Reported Outcomes as Motivation to  
Develop New Therapeutic Strategies

Clinical Problems to be Addressed by  
Pharmacoepidemiologic Research

Methodologic Problems to be Solved by  
Pharmacoepidemiologic Research

Currently Available Solutions

The Future

Further Reading

## 20 The Use of Meta-analysis in Pharmacoepidemiology

Introduction

Clinical Problems to be Addressed by  
Pharmacoepidemiologic Research

[Methodological Problems to be Solved by  
Pharmacoepidemiologic Research](#)

[Currently Available Solutions](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)

## [21 Studies of Medication Adherence](#)

[Introduction](#)

[Clinical Problems to be Addressed by  
Pharmacoepidemiologic Research](#)

[Methodological Problems to be Addressed by  
Pharmacoepidemiologic Research](#)

[Currently Available Solutions](#)

[Analysis Issues in Adherence](#)

[The Future](#)

[Key Points](#)

[Further Reading](#)

## [22 Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies](#)

[Introduction](#)

[Clinical Problems to be Addressed by  
Pharmacoepidemiologic Research](#)

[Methodological Problems to be Addressed by  
Pharmacoepidemiologic Research](#)

[Currently Available Solutions](#)

[Conclusion](#)

[Key Points](#)

[Further Reading](#)

[Part IV: Special Applications and the Future of  
Pharmacoepidemiology](#)

## [23 Special Applications of Pharmacoepidemiology](#)

[Studies of Drug Utilization](#)

[Evaluating and Improving Prescribing](#)

[Special Methodological Issues in Pharmacoepidemiologic Studies of Vaccine Safety](#)

[Epidemiologic Studies of Implantable Medical Devices](#)

[Research on the Effects of Medications in Pregnancy and in Children](#)

[Risk Management](#)

[The Pharmacoepidemiology of Medication Errors](#)

[Benefit-Risk Assessments of Medical Treatments](#)

[Further Reading](#)

## [24 The Future of Pharmacoepidemiology](#)

[Introduction](#)

[The View from Academia](#)

[The View from Industry](#)

[The View from Regulatory Agencies](#)

[The View from the Law](#)

[Conclusion](#)

[Key Points](#)

[Further Reading](#)

[Sample Size Tables](#)

[Glossary](#)

[Index](#)

[End User License Agreement](#)

# List of Tables

## Chapter 1

[Table 1.1 Potential contributions of pharmacoepidemiology.](#)

## Chapter 2

[Table 2.1 Types of associations between factors under study.](#)

[Table 2.2 Approaches to controlling confounding.](#)

[Table 2.3 Criteria for the causal nature of an association.](#)

[Table 2.4 Advantages and disadvantages of epidemiologic study designs.](#)

[Table 2.5 Epidemiologic study designs.](#)

## Chapter 3

[Table 3.1 Information needed to calculate a study's sample size.](#)

[Table 3.2 Examples of sample sizes needed for a cohort study.](#)

[Table 3.3 Examples of sample sizes needed for a case-control study.](#)

## Chapter 4

[Table 4.1 Physiologic systems affected during aging that influence drug pha...](#)

[Table 4.2 FDA categories of drug safety during pregnancy.](#)

## Chapter 5

[Table 5.1 Reasons to perform pharmacoepidemiologic studies.](#)

[Table 5.2 Factors affecting the acceptability of risks.](#)

[Table 5.3 Annual risks of death from some selected hazards.](#)

## Chapter 6

[Table 6.1 Bradford Hill criteria.](#)

[Table 6.2 Potentially objectionable language in research contracts for phar...](#)

## Chapter 9

[Table 9.1 Core data domains in encounter databases<sup>a</sup>.](#)

[Table 9.2 Select database characteristics.](#)

## Chapter 10

[Table 10.1 Overview of EHR databases.](#)

[Table 10.2 Selected variables in EHR databases available for epidemiologic ...](#)

## Chapter 12

[Table 12.1 Comparative characteristics of pharmacoepidemiologic data resour...](#)

[Table 12.2 Characteristics of research questions and their impact on the ch...](#)

## Chapter 13

[Table 13.1 Sensitivity, specificity, PPV and NPV for three algorithms.](#)

[Table 13.2 Sensitivity, specificity, PPV and NPV for claims-based diagnoses...](#)

## Chapter 15

[Table 15.1 Hypothetical response to medications by genetic variants in meta...](#)

[Table 15.2 Two ways to present effect modification in molecular pharmacoepi...](#)

[Table 15.3 Gene-exposure interaction analysis in a case-control study.](#)

## Chapter 17

[Table 17.1 Typical design characteristics of a large simple trial \(LST\) com...](#)

[Table 17.2 Conditions appropriate for the conduct of a large simply randomiz...](#)

[Table 17.3 Conditions which make a large, simple randomized trial feasible.](#)

## Chapter 22

[Table 22.1 Hypothetical data for 10 subjects with ventricular tachycardia i...](#)

[Table 22.2 Illustration of a case-time-control analysis of data from a case...](#)

## Chapter 23

[Table 23.1 Drug utilization studies in perspective: operational concepts.](#)

[Table 23.2 Steps in the BRAT benefit-risk framework.](#)

[Table 23.3 Effects table for atrial fibrillation \(simulated data\).](#)

## Sample Size Tables

[Table A1 Sample sizes for cohort studies<sup>a</sup>.](#)

[Table A2 Sample size for cohort studies<sup>a</sup>.](#)

[Table A3 Sample sizes for cohort studies<sup>a</sup>.](#)  
[Table A4 Sample sizes for cohort studies<sup>a</sup>.](#)  
[Table A5 Sample sizes for cohort studies<sup>a</sup>.](#)  
[Table A6 Sample sizes for cohort studies<sup>a</sup>.](#)  
[Table A7 Sample sizes for cohort studies<sup>a</sup>.](#)  
[Table A8 Sample sizes for cohort studies<sup>a</sup>.](#)  
[Table A9 Sample sizes for case-control studies<sup>a</sup>.](#)  
[Table A10 Sample sizes for case-control studies<sup>a</sup>.](#)  
[Table A11 Sample size for case-control studies<sup>a</sup>.](#)  
[Table A12 Sample sizes for case-control studies<sup>a</sup>.](#)  
[Table A13 Sample sizes for case-control studies<sup>a</sup>.](#)  
[Table A14 Sample sizes for case-control studies<sup>a</sup>.](#)  
[Table A15 Sample sizes for case-control studies<sup>a</sup>.](#)  
[Table A16 Sample sizes for case-control studies<sup>a</sup>.](#)  
[Table A17 Tabular values of 95% confidence limit factors for estimates of a pois...](#)

## List of Illustrations

### Chapter 2

[Figure 2.1 Overview of the scientific method.](#)

[Figure 2.2 Cohort and case-control studies provide similar information, but ...](#)

### Chapter 4

[Figure 4.1 Relationship between clinical pharmacology and pharmacoepidemiolo...](#)

[Figure 4.2 Semi-logarithmic plot of concentration vs time after an intraveno...](#)

[Figure 4.3 Representative pharmacodynamic relationships for drugs which exhi...](#)

[Figure 4.4 Concentration-time, hysteresis, and effect-concentration plots \(c...](#)

[Figure 4.5 The MIDD approach learns and confirms key characteristics of new ...](#)

## Chapter 8

[Figure 8.1 Sources of claims data.](#)

## Chapter 13

[Figure 13.1 Formulas for calculating sensitivity and specificity.](#)

[Figure 13.2 Formulas for calculating the percent agreement and  \$\kappa\$ .](#)

[Figure 13.3 Small amount of measurement error can cause large error in study...](#)

[Figure 13.4 Recall schematic for showing how date of depression diagnosis wa...](#)

## Chapter 14

[Figure 14.1 Simplified presentation of method proposed by Naranjo et al. Lik...](#)

## Chapter 18

[Figure 18.1 Moral Hazard and Product Choice. Note: Cost \(No insurance\)-assum...](#)

[Figure 18.2 The three dimensions of economic evaluation of clinical care....](#)

[Figure 18.3 Cost and clinical outcomes.](#)



[Figure 18.4 Specialty Pharmaceuticals and Premiums.](#)

## Chapter 20

[Figure 20.1 Forest plot of four recent observational studies on the effect o...](#)

[Figure 20.2 Funnel plot for published 34 studies only: analysis of data from...](#)

[Figure 20.3 Funnel plot for published 34 studies \(open boxes\) and unpublishe...](#)

[Figure 20.4 Results of 17 RCTs of the effect of oral beta-blockers for secon...](#)

## Chapter 21

[Figure 21.1 Phases and taxonomy of adherence.](#)

[Figure 21.2 Example of implementation and persistence measures in pharmacy d...](#)

## Chapter 22

[Figure 22.1 Principle of the new user design and its variations when studyin...](#)

[Figure 22.2 Study design choice by source of exposure variation.](#)

[Figure 22.3 Illustration of a \*calendar-time\* cohort of 21 subjects foll...](#)

[Figure 22.4 Illustration of \*follow-up-time\* cohort representation...](#)

[Figure 22.5 Nested case-control sample of one control \(■\) per case \(•\) from ...](#)

[Figure 22.6 Case-cohort sample with six controls \(■\) from cohort in Figure 2...](#)

[Figure 22.7 Two hypothetical propensity score distributions before and after...](#)

## Chapter 23

[Figure 23.1 Example value trees for treatment of atrial fibrillation. \(a\) Ou...](#)

[Figure 23.2 Forest plot showing rate differences per 10 000 person-years for...](#)

[Figure 23.3 Demonstration of the impact of dependencies between outcomes. Bo...](#)

# **Textbook of Pharmacoepidemiology**

Third Edition

*Edited by*

**Brian L. Strom, MD, MPH**

*Chancellor, Rutgers Biomedical & Health Sciences*

*Executive Vice President for Health Affairs*

*University Professor*

*Rutgers, The State University of New Jersey*

*Newark, NJ, USA*

**Stephen E. Kimmel, MD, MSCE**

*Dean's Professor and Chair of Epidemiology*

*College of Public Health and Health Professions and*

*College of Medicine*

*University of Florida*

*Gainesville, FL, USA*

**Sean Hennessy, PharmD, PhD**

*Professor of Epidemiology*

*Director, Center for Pharmacoepidemiology Research and  
Training*

*University of Pennsylvania Perelman School of Medicine*

*Philadelphia, PA, USA*

**WILEY** Blackwell

This edition first published 2022  
© 2022 John Wiley & Sons Ltd

*Edition History*

*John Wiley & Sons Ltd (1e, 2006);  
John Wiley & Sons Ltd (2e, 2013)*

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Brian L. Strom, Stephen E. Kimmel, Sean Hennessy to be identified as the authors of the editorial material in this work has been asserted in accordance with law.

*Registered Offices*

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA  
John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

*Editorial Office*

9600 Garsington Road, Oxford, OX4 2DQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at [www.wiley.com](http://www.wiley.com).

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

*Limit of Liability/Disclaimer of Warranty*

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and

authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

*Library of Congress Cataloging-in-Publication Data*

Names: Strom, Brian L., editor. | Kimmel, Stephen | Hennessy, Sean, editor. E., editor.

Title: Textbook of pharmacoepidemiology / edited by Brian L. Strom, Sean Hennessy, Stephen E. Kimmel.

Description: Third edition. | Hoboken, NJ : Wiley-Blackwell, 2021. | Includes bibliographical references and index.

Identifiers: LCCN 2021029285 (print) | LCCN 2021029286 (ebook) | ISBN 9781119701071 (paperback) | ISBN 9781119701088 (adobe pdf) | ISBN 9781119701118 (epub)

Subjects: MESH: Pharmacoepidemiology--methods

Classification: LCC RM302.5 (print) | LCC RM302.5 (ebook) | NLM QV 771 | DDC 615.7/042-dc23

LC record available at <https://lcn.loc.gov/2021029285>

LC ebook record available at <https://lcn.loc.gov/2021029286>

Cover Design: Wiley

Cover Image: © ShutterWorx/Getty Images r.classen/Shutterstock

# List of Contributors

## ***Trisha Acri***

Department of Family and Community  
Medicine Temple University School of Medicine  
Philadelphia, PA, USA  
Currently, Director of Community Research  
Health Services, AIDS Care Group, AIDS Care Group,  
Sharon Hill, PA, USA

## ***Jerry Avorn***

Harvard Medical School and Brigham and Women's  
Hospital  
Boston, MA, USA

## ***Jeffrey S. Barrett***

Critical Path Institute  
Tucson, AZ, USA

## ***David W. Bates***

Division of General Internal Medicine and Primary Care  
Brigham and Women's Hospital and Harvard Medical  
School  
Boston, MA, USA

## ***Bernard Bégaud***

Clinical Pharmacology and Pharmacoepidemiology, Medical  
School  
University of Bordeaux  
Bordeaux, France

## ***Jesse A. Berlin***

Johnson & Johnson  
Titusville, NJ, USA

## ***Harshvinder Bhullar***

Independent Consultant London, UK

***Laura E. Bothwell***

Yale School of Public Health  
New Haven, Connecticut, USA

***Adam C. Carle***

Cincinnati Children's Hospital Medical Center Cincinnati,  
OH, USA

University of Cincinnati, College of Medicine Cincinnati,  
OH, USA

University of Cincinnati, College of Arts and Sciences  
Cincinnati, OH, USA

***Robert T. Chen***

Brighton Collaboration, Task Force for Global Health  
Decatur, GA, USA

***Emil Cochino***

European Medicines Agency  
Amsterdam, The Netherlands

***Brenda J. Crowe***

Eli Lilly and Company  
Indianapolis, IN, USA

***Francesca Cunningham***

US Department of Veterans Affairs  
Hines, IL, USA

***Gerald J. Dal Pan***

Office of Surveillance and Epidemiology  
Center for Drug Evaluation and Research  
US Food and Drug Administration  
Silver Spring, MD, USA

***Rachael L. DiSantostefano***

Department of Epidemiology  
Janssen Research & Development  
Titusville, NJ, USA



***Scott Evans***

Biostatistics Center  
The George Washington University  
Rockville, MD, USA

***Stephen J.W. Evans***

The London School of Hygiene and Tropical  
Medicine, London, UK

***Joshua J. Gagne***

Harvard Medical School and Brigham and Women's  
Hospital, Boston, MA, USA  
and Johnson and Johnson  
New Brunswick, NJ, USA

***Nicolle M. Gatto***

Aetion Inc., New York, NY, USA

***Kate Gelperin***

Division of Epidemiology Office of Surveillance and  
Epidemiology  
Center for Drug Evaluation and Research  
US Food and Drug Administration  
Silver Spring, MD, USA

***Tobias Gerhard***

Ernest Mario School of Pharmacy  
Rutgers Biomedical and Health Sciences Piscataway, NJ,  
USA  
and  
Center for Pharmacoepidemiology and Treatment Science  
Rutgers Biomedical and Health Sciences  
New Brunswick, NJ, USA

***Jeremy Greene***

Johns Hopkins University  
Baltimore, Maryland, MD, USA

***Robert Gross***

Center for Clinical Epidemiology and Biostatistics

Center for Pharmacoepidemiology Research and Training,  
Perelman School of Medicine University of Pennsylvania,  
Philadelphia PA, USA

***Sean Hennessy***

University of Pennsylvania Perelman School of Medicine  
Philadelphia, PA, USA

***Sonia Hernandez Diaz***

Harvard T.H. Chan School of Public Health  
Boston, MA, USA

***Daniel B. Horton***

Rutgers Robert Wood Johnson  
Medical School, Rutgers Center for Pharmacoepidemiology  
and Treatment Science, Rutgers School of Public Health  
New Brunswick, NJ, USA

***Krista F. Huybrechts***

Brigham and Women's Hospital  
Harvard Medical School  
Boston, MA, USA

***Judith K. Jones***

<sup>†</sup>Formerly Principal Consultant PharmaLex, Inc., Fairfax,  
VA and Adjunct Faculty  
The University of Michigan School of Public  
Health Summer Program  
Ann Arbor, USA

***Aaron S. Kesselheim***

Harvard Medical School and Brigham and Women's  
Hospital  
Boston, MA, USA

***Stephen E. Kimmel***

University of Florida College of Public  
Health and Health Professions & College of Medicine  
Gainesville, FL, USA

***Tamar Lasky***

US Food and Drug Administration Silver Spring, MD, USA

***Julie Lauffenburger***

Brigham and Women's Hospital and Harvard Medical  
School  
Boston, MA, USA

***David Lee***

Center for Pharmaceutical Management Management  
Sciences for Health  
Arlington, VA, USA

***Samuel M. Lesko***

Northeast Regional Cancer Institute and Geisinger  
Commonwealth School of Medicine  
Scranton, PA, USA

***Bennett Levitan***

Department of Epidemiology Janssen Research &  
Development  
Titusville, NJ, USA

***Marie Lindquist***

Uppsala Monitoring Centre  
WHO Collaborating Centre for International Drug  
Monitoring  
Uppsala, Sweden

***Christine Y. Lu***

Harvard Medical School and Harvard Pilgrim  
Health Care Institute, Boston, MA, USA

***George Maldonado***

Division of Environmental Health Sciences  
School of Public Health, University of Minnesota,  
Minneapolis, MN, USA

***Claudia Manzo***

Division of Risk Management Office of Surveillance and

Epidemiology  
Center for Drug Evaluation and Research  
US Food and Drug Administration  
Silver Spring, MD, USA

***Danica Marinac-Dabic***

Division of Epidemiology  
Office of Surveillance and Biometrics Center for Devices  
and Radiological Health  
US Food and Drug Administration  
Silver Spring, MD, USA

***Allen A. Mitchell***

Slone Epidemiology Center at Boston  
University, Boston, MA, USA

***Jingping Mo***

Epidemiology, Worldwide Research & Development, Pfizer  
Inc.  
New York, NY, USA

***Esi M. Morgan***

Seattle Children's Hospital  
Seattle, WA, USA  
University of Washington  
Seattle, WA, USA

***Yola Moride***

Center for Pharmacoepidemiology and Treatment Science,  
Rutgers Biomedical and Health Sciences  
New Brunswick, NJ, USA

***Sharon-Lise T. Normand***

Harvard Medical School and  
Harvard School of Public Health  
Boston, MA, USA

***Anton Pottegård***

Clinical Pharmacology and Pharmacy  
Department of Public Health

University of Southern Denmark  
Odense, Denmark

***Nicole Pratt***

Quality Use of Medicines and Pharmacy  
Research Centre, Clinical and Health Sciences  
University of South Australia, Adelaide, South Australia,  
Australia

***June Raine***

Vigilance and Risk Management of Medicine  
Medicines and Healthcare Products  
Regulatory Agency, London, UK

***Robert F. Reynolds***

Epidemiology, Research and Development,  
GlaxoSmithKline, New York, NY, USA

***Annika Richterich***

Maastricht University  
Maastricht, The Netherlands

***Mary Elizabeth Ritchey***

Med Tech Epi, LLC, Philadelphia, PA, USA  
Center for Pharmacoepidemiology and Treatment Science,  
Rutgers University  
New Brunswick, NJ, USA

***Sebastian Schneeweiss***

Departments of Medicine and Epidemiology  
Harvard Medical School and Division of  
Pharmacoepidemiology Department of Medicine  
Brigham & Women's Hospital  
Boston, MA, USA

***Kevin A. Schulman***

Clinical Excellence Research Center  
Stanford University  
Stanford, CA, USA

***Art Sedrakyan***

Department of Public Health  
New York Presbyterian Hospital and Weill Cornell Medical  
College  
New York, NY, USA

***Hanna M. Seidling***

Head of Cooperation Unit Clinical Pharmacy  
Department of Clinical Pharmacology and  
Pharmacoepidemiology Cooperation Unit Clinical Pharmacy  
University of Heidelberg  
Heidelberg, Germany

***Stephen B. Soumerai***

Department of Population Medicine Director  
Drug Policy Research Group  
Harvard Medical School and Harvard Pilgrim  
Health Care Institute  
Boston, MA, USA

***Brian L. Strom***

Rutgers Biomedical and Health Sciences  
Newark, NJ, USA

***Samy Suissa***

McGill University and Jewish General Hospital  
Montreal, Quebec, Canada

***Janet Sultana***

Mater Dei Hospital, Msida, Malta and Exeter College of  
Medicine and Health  
University of Exeter, Exeter, UK

***Gianluca Trifirò***

Department of Diagnostics and Public Health  
University of Verona, Verona, Italy

***Shinobu Uzu***

Pharmaceuticals and Medical Devices Agency  
Tokyo, Japan